f-627
Neutropenia
EVIVE BiotechnologyPhase 3Dormant
BBB
79/ 100
Provisional rating · Methodology v0.2
Rating breakdown
- Clinical Evidence
- 78/ 100
- Competitive Position
- 81/ 100
Competitive context
18 Active assets in the Neutropenia cohort.
| Asset / Sponsor | Phase | Rating |
|---|---|---|
FILGRASTIM Cancer Institute and Hospital, Chinese Academy of Medical Sciences | Phase 4 | BBB |
PEGFILGRASTIM Affiliated Hospital of North Sichuan Medical College | Phase 4 | BBB |
Cefepime Hospital Universitari Vall d'Hebron Research Institute | Phase 4 | BB |
Cyclophosphamide Spectrum Pharmaceuticals, Inc | Phase 3 | BB |
Docetaxel Spectrum Pharmaceuticals, Inc | Phase 3 | BB |
View all 50 →
Same molecule, other indications
f-627 is also rated in:
Are you the sponsor?
Submit your data room for a Verified Rating. The public-data rating remains visible alongside.
Contact →